A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates

Journal of Pharmaceutical and Biomedical Analysis

Volumn 71, Issue , 2012, Pages 99-103

  Ito, Hajime ^a   Yamaguchi, Hiroaki ^a   Fujikawa, Asuka ^a   Tanaka, Nobuaki ^a   Furugen, Ayako ^a   Miyamori, Kazuaki ^a   Takahashi, Natsuko ^b   Ogura, Jiro ^a   Kobayashi, Masaki ^a   Yamada, Takehiro ^c   Mano, Nariyasu ^d   Iseki, Ken ^a,c  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^d TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hydrophilic interaction liquid chromatography tandem mass spectrometry; Oxaliplatin; Plasma ultrafiltrates

Indexed keywords

ACETONITRILE; CARBOPLATIN; OXALIPLATIN;

ACCURACY; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYDROPHILIC INTERACTION CHROMATOGRAPHY; IONIZATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ACETONITRILES; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; COLORECTAL NEOPLASMS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ORGANOPLATINUM COMPOUNDS; PHOSPHORYLCHOLINE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION;

EID: 84866751424     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.08.010     Document Type: Article

References (18)

1. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
2. Welch S., Spithoff K., Rumble R.B., Maroun J. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann. Oncol. 2010, 21:1152-1162.
3. Egorin M.J., Van Echo D.A., Tipping S.J., Olman E.A., Whitacre M.Y., Thompson B.W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res. 1984, 44:5432-5438.
4. Hanada K., Suda M., Kanai N., Ogata H. Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives. Pharm. Res. 2010, 27:1893-1899.
5. Burger H., Loos W.J., Eechoute K., Verweij J., Mathijssen R.H., Wiemer E.A. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist. Updat. 2011, 14:22-34.
6. Kloft C., Appelius H., Siegert W., Schunack W., Jaehde U., Kloft C., Appelius H., Siegert W., Schunack W., Jaehde U. Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay. Ther. Drug Monit. 1999, 21:631-637.
7. Morrison J.G., White P., McDougall S., Firth J.W., Woolfrey S.G., Graham M.A., Greenslade D. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J. Pharm. Biomed. Anal. 2000, 24:1-10.
8. Ficarra R., Calabro M.L., Cutroneo P., Tommasini S., Melardi S., Semreen M., Furlanetto S., Ficarra P., Altavilla G. Validation of a LC method for the analysis of oxaliplatin in a pharmaceutical formulation using an experimental design. J. Pharm. Biomed. Anal. 2002, 29:1097-1103.
9. Kizu R., Yamamoto T., Yokoyama T., Tanaka M., Miyazaki M. A sensitive postcolumn derivatization/UV detection system for HPLC determination of antitumor divalent and quadrivalent platinum complexes. Chem. Pharm. Bull. 1995, 43:108-114.
10. Ehrsson H., Wallin I. Liquid chromatographic determination of oxaliplatin in blood using post-column derivatization in a microwave field followed by photometric detection. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2003, 795:291-294.
11. Luo F.R., Yen T.Y., Wyrick S.D., Chaney S.G. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J. Chromatogr. B: Biomed. Sci. Appl. 1999, 724:345-356.
12. Zhang W., Seymour L., Chen E.X. Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 876:277-282.
13. Naidong W. Bioanalytical liquid chromatography-tandem mass spectrometry methods on underivatized silica columns with aqueous/organic mobile phases. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2003, 796:209-224.
14. Hemstrom P., Irgum K. Hydrophilic interaction chromatography. J. Sep. Sci. 2006, 29:1784-1821.
15. McCalley D.V. Is hydrophilic interaction chromatography with silica columns a viable alternative to reversed-phase liquid chromatography for the analysis of ionisable compounds?. J. Chromatogr. A 2007, 1171:46-55.
16. Dejaegher B., Mangelings D., Heyden Y.V. Method development for HILIC assays. J. Sep. Sci. 2008, 31:1438-1448.
17. Hemström P., Nygren Y., Björn E., Irgum K. Alternative organic solvents for HILIC separation of cisplatin species with on-line ICP-MS detection. J. Sep. Sci. 2008, 31:599-603.
18. Falta T., Koellensperger G., Standler A., Buchberger W., Mader R.M., Hann S. Quantification of cisplatin, carboplatin and oxaliplatin in spiked human plasma samples by ICP-SFMS and hydrophilic interaction liquid chromatography (HILIC) combined with ICP-MS detection. J. Anal. At. Spectrom. 2009, 24:1336-1342.